Navigation Links
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine
Date:12/7/2009

RECHOVOT, Israel, Dec. 7 /PRNewswire/ --

  • 60 people, males and females, aged 18-49, participated in the trial
  • The antibodies generated by the vaccine specifically identified several strains of influenza, including the swine flu strain
  • BiondVax's CEO Dr. Ron Babecoff: "This is an important indication along the way towards the realization of the Company's vision of ensuring protection against all flu strains with a single vaccination."

BiondVax Pharmaceuticals Ltd. (TASE: BNDK), an Israeli biopharmaceutical company at the forefront of the development of a Universal Influenza Vaccine, announced the success of the Phase I/II clinical trial of the Company's Multimeric-001 Universal Flu Vaccine, in trials conducted at the Sourasky Medical Center in Tel Aviv, Israel. The Phase I/II trial was a randomized, single-blind, placebo-controlled, escalating double-dose safety study in which a total of 60 participants, males and females aged 18-49, received two intramuscular injections containing the Multimeric-001 vaccine, either with or without adjuvant, and at two different dose levels.

The clinical trial results show that BiondVax's Multimeric-001 Universal Flu Vaccine is safe to use at all doses tested, both with and without adjuvant.

In addition, it was found that the Multimeric-001 Universal Flu Vaccine activated, in a statistically significant manner when compared with placebo, the two arms of the human immune system - the humoral (antibody) arm and the cellular arm. All participants who received the vaccine showed a high level of antibodies against the Multimeric-001 Universal Flu Vaccine. These antibodies also specifically identified a number of different strains of influenza, including the swine flu strain (A/H1N1).

In this Phase I/II clinical trial, certain cellular parameters were examined, and it was found that the Multimeric-001 Universal Flu Vaccine caused, in a statistically significant manner when compared with placebo, a meaningful increase in the white blood cells of the immune system, inducing the secretion of Interferon Gamma and Interleukin-2, substances secreted by the immune system as part of the body's cellular defense against pathogens. This cellular response distinguishes BiondVax's Multimeric-001 Universal Flu Vaccine from existing seasonal flu vaccines, which are characterised mainly by their ability to stimulate a humoral (antibody) response.

Furthermore, it was found that BiondVax's Multimeric-001 Universal Flu Vaccine stimulated both humoral (antibody) and cellular responses against the two types of influenza: Influenza Type A and Influenza Type B, the types of flu which cause the flu disease in humans. This is in contrast to other universal vaccines that are currently under development, which, to the Company's best knowledge based on scientific publications and other sources, are intended to provide protection against Type A influenzas only.

In the clinical trial it was found, in a statistically significant manner when compared with placebo, that the highest immunogenicity was observed when using the highest dose of the Multimeric-001 Universal Flu Vaccine with adjuvant, which was injected twice to the participants. Similarly, it was found that in the dose given twice without adjuvant, there was a statistically significant response.

This trial is the first of two Phase I/II clinical trials of the Multimeric-001 Universal Flu Vaccine being conducted by BiondVax - the second trial has already commenced with 60 participants aged 55-75, and is expected to be completed in the first quarter of 2010.

Dr. Ron Babecoff, BiondVax CEO, notes that "We are very proud of the success of the Phase I/II clinical trial for the Multimeric-001 Universal Flu Vaccine, and of this initial proof of the immunogenicity and safety of our vaccine. The results obtained in this trial are an important indication of a significant milestone towards the realization of the Company's vision of ensuring protection against all flu strains through the use of a single vaccine. Such a vaccine is expected to do away with the need for annual vaccinations every year as required by current existing vaccines."

Dr. Tamar Ben Yedidia, BiondVax's Director of R&D, notes that, "the success of the trial proved that the Multimeric-001 Universal Flu Vaccine is safe to use and activates both arms of the human immune system. This is an important achievement, which will continue to be tested thoroughly in further clinical trials that will be conducted".

Dr. Ben Yedidia will be presenting this data at the World Influenza Congress in Brussels, Belgium, on 8 December 2009, in a presentation entitled "Delivering an Epitope-based Approach to Universal Influenza Vaccine Development".



For further information, please contact:

BiondVax Pharmaceuticals Ltd.:
Dr. Ron Babecoff, President & CEO         Tel: +972-8-930-2529
                                          info@biondvax.com

Media:
Nancy Shapira-Aronovic                    Tel: +972-3-607-0588
Public Relations Consultant               Mob: +972-54-486-3888
Gelbart-Kahana                            nancy@gksmarketing.com



Notes to Editors

About BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals ("the Company"), a publicly-traded company (TASE: BNDK) based in Rechovot, Israel, is developing a proprietary, innovative Universal Influenza ("flu") Vaccine, the Multimeric-001 vaccine, with the potential to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.

BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Weizmann Institute Professor Ruth Arnon, who heads the Company's Scientific Advisory Board. Professor Arnon is well-known for her part in the development of Copaxone®, a blockbuster drug for the treatment of multiple sclerosis. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative Universal Flu Vaccine.

BiondVax is currently testing its lead product, the Multimeric-001 vaccine, in two Phase I/II clinical trials.

BiondVax's team includes scientists, technicians, researchers, and administrative staff. The Company's state-of-the-art GMP facility, located in the Weizmann Science Park in Rechovot, houses its laboratories, production facilities, and offices.

For further information on BiondVax, please visit the Company's website: www.biondvax.com

For logos, pictures and other company information please visit:

http://www.biondvax.com/128084/Press-Kit-1-1

For information on BiondVax in the news, please visit:

http://www.biondvax.com/128084/BiondVax-in-the-News-1

Forward Looking Statements

Statements included herein that are not historical facts are "forward-looking statements" within the meaning of applicable securities laws. These forward-looking statements involve risks and uncertainties, including those identified within the "Risk Factors" section of the Company's Shelf Prospectus dated 26 November 2009.

Although management of the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, the Company cannot assure investors that these expectations will prove correct, and the actual results that the Company achieves may differ materially from any forward-looking statements, due to such risks and uncertainties.

SOURCE BiondVax Pharmaceuticals Ltd.


'/>"/>
SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
2. Phonak Successfully Hosts Hearing Care for Adults 2009 Conference
3. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
4. L.A. Zoo Announces Successful Cancer Treatment of Rhinoceros With Electronic Brachytherapy
5. London Genetics Focuses on Partnering Following Successful Pharmacogenetics Conference
6. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
7. Reportlinker Adds Driving Successful Pharma Brands: Case Studies of Real Product Launches
8. Educating the Marketplace to Support Successful Oncology Product Launches
9. Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections
10. Dartmouth Medical School Faculty Member and Anesthesiologist Invents Revolutionary Catheter System Designed to Increase Rate of Successful IV Insertions by 75 Percent
11. DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):